Zidesamtinib is having a hard time catching up with Ibtrozi's line-agnostic approval.
ApexOnco Front Page
Recent articles
The companies have trumped Gilead’s Trodelvy with a lung cancer approval.
Suzhou Zelgen’s DLL3 x DLL3 project looks better than regular T-cell engagers, with caveats.
The players are vying in the CD19 x CD20 Car-T arena.
The company sees an improvement with a Tecvayli/Talvey combo vs either monotherapy.
INCA033989 looks potent in essential thrombocythemia, but already the opportunity looks tiny.
The Enliven molecule looks competitive against Scemblix, triggering a $200m raise.
But the former is paying a fraction of what Merck shelled out for raludotatug.
